

1 **Persistent Inequities in Intravenous Thrombolysis for Acute Ischemic Stroke in the United**
2 **States: Results from the Nationwide Inpatient Sample**

3

4 Philip Sun, MD MS^{1,2}; Ling Zheng, PhD²; Michelle Lin, MD MPH³; Steven Cen, PhD²; Gmerice
5 Hammond, MD MPH⁴; Karen E. Joynt Maddox, MD MPH^{4,5}; May Kim-Tenser, MD²; Nerses
6 Sanossian, MD^{1,2}; William Mack, MD⁶; Amytis Towfighi, MD^{1,2}

7

8 ¹Department of Neurology, David Geffen School of Medicine at University of California - Los
9 Angeles, Los Angeles, CA; ²Department of Neurology, Keck School of Medicine, University of
10 Southern California, Los Angeles, CA; ³Department of Neurology, Mayo Clinic, Jacksonville,
11 FL; ⁴Department of Medicine, Cardiovascular Division, Washington University School of
12 Medicine, St. Louis, MO; ⁵Center for Advancing Health Services, Policy & Economics
13 Research, Institute for Public Health at Washington University, St. Louis MO; ⁶Department of
14 Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles,
15 CA

16

17 ADDRESS CORRESPONDENCE TO:

18 Philip Young-woo Sun, MD

19 Department of Neurology

20 David Geffen School of Medicine at University of California - Los Angeles

21 710 Westwood Plaza, Rm 1-240

22 Los Angeles, CA 90095

23 Phone: 213-605-5839

- 24 Email: philipsun@mednet.ucla.edu
- 25 **Key words:** thrombolysis, sex differences, ethnicity, epidemiology, inequities
- 26
- 27 **Word count (abstract):** 328
- 28 **Word count (full text):** 3131
- 29 **Tables:** 2
- 30 **Supplemental Tables:** 3
- 31 **Figures:** 2
- 32 **References:** 30

33 **Abstract**

34 **Background:** Despite its approval for use in acute ischemic stroke (AIS) >25 years ago,
35 intravenous thrombolysis (IVT) remains underutilized, with inequities by age, sex, race/ethnicity,
36 and geography. Little is known about IVT rates by insurance status. We aimed to assess temporal
37 trends in the inequities in IVT use.

38 **Methods:** We assessed trends from 2002 to 2015 in IVT for AIS in the Nationwide Inpatient
39 Sample by sex, age, race/ethnicity, hospital location/teaching status, and insurance, using survey-
40 weighted logistic regression, adjusting for sociodemographics, comorbidities, and hospital
41 characteristics. We calculated odds ratios for IVT for each category in 2002-2008 (*Period 1*) and
42 2009-2015 (*Period 2*).

43 **Results:** Among AIS patients (weighted N=6,694,081), IVT increased from 1.0% in 2002 to 6.8%
44 in 2015 (adjusted annual relative ratio (AARR) 1.15, 95% CI 1.14-1.16). Individuals ≥ 85 years
45 had the most pronounced increase from 2002 to 2015 (AARR 1.18, 1.17-1.19), but were less
46 likely to receive IVT compared to those aged 18-44 years in both Period 1 (adjusted odds ratio
47 (aOR) 0.23, 0.21-0.26) and Period 2 (aOR 0.36, 0.34-0.38). Women were less likely than men to
48 receive IVT, but the disparity narrowed over time (Period 1 aOR 0.81, 0.78-0.84, Period 2 aOR
49 0.94, 0.92-0.97). Inequities in IVT by race/ethnicity resolved for Hispanic individuals in Period 2
50 but not for Black individuals (Period 2 aOR 0.81, 0.78-0.85). The disparity in IVT for Medicare
51 patients, compared to privately insured patients, lessened over time (Period 1 aOR 0.59, 0.56-
52 0.52, Period 2 aOR 0.75, 0.72-0.77). Patients treated in rural hospitals were less likely to receive
53 IVT than those treated in urban hospitals; a more dramatic increase in urban areas widened the
54 inequity (Period 2 urban non-teaching vs. rural aOR 2.58, 2.33-2.85, urban teaching vs. rural
55 aOR 3.90, 3.55-4.28).

56 **Conclusion:** From 2002 through 2015, IVT for AIS increased among adults. Despite
57 encouraging trends, only 1 in 15 AIS patients received IVT and persistent inequities remained
58 for Black individuals, women, government-insured, and those treated in rural areas, highlighting
59 the need for intensified efforts at addressing inequities.

60

61 **Introduction**

62 Administration of intravenous thrombolysis (IVT) with recombinant tissue plasminogen
63 activator in appropriately selected patients with acute ischemic stroke (AIS) is associated with
64 improved mortality and functional outcomes^{1,2}. With expansion of evidence-based systems of
65 care, such as primary and comprehensive stroke center designation, IVT use has become more
66 widespread over time in the United States,³⁻⁶ though it remains significantly underused in eligible
67 populations.

68 Additionally, marked inequities remain by sex⁷, age³, race/ethnicity^{7,8}, and geographic
69 location^{4,6,9}. For example, women are less likely to receive IVT than men, and individuals
70 admitted to rural hospitals are less likely to receive IVT than those admitted to urban hospitals^{3,7}.
71 While some sociodemographic inequities in IVT use have improved over the past few decades
72 (e.g. use of IVT in individuals ≥ 85 years³ from 2005 to 2010), others remain unresolved or have
73 worsened (e.g. for women from 2007 to 2011⁷, for Black and Hispanic individuals from 2004 to
74 2010⁸, for all non-White individuals from 2007 to 2011⁷ and for people living in rural areas from
75 2000 to 2010⁴ and 2012 to 2017⁹).

76 Furthermore, although one could postulate that use of evidence-based protocols would
77 reduce disparities, a recent study revealed that presentation to a primary stroke center enhanced
78 rate of IVT use overall but did not alleviate racial disparities⁸.

79 Little is known about more recent temporal trends in IVT use by sex, race/ethnicity, age,
80 and hospital location/teaching status. Additionally, to our knowledge, differences in IVT by
81 insurance type have not been studied in the United States. Therefore, the aim of the study was to
82 fill these gaps by evaluating recent temporal trends in IVT among individuals with AIS, stratified
83 by age, race/ethnicity, sex, primary insurance, hospital teaching status, and urban/rural location

84 using data from the National Inpatient Sample (NIS) from 2002 to 2015. We hypothesized an
85 overall increase in IVT and reduction in inequities over the study period.

86

87 **Methods:**

88 **Population for Study**

89 Data were obtained from the National Inpatient Sample (NIS), which was developed as
90 part of the Healthcare Cost and Utilization Project (HCUP). Prior to 2012, the survey was
91 designed to approximate a stratified 20% sample of all United States community hospitals (non-
92 federal, short-term, general, and specialty hospitals) serving adults in the United States. From
93 2012, the sampling strategy transitioned to 20% of patient discharges from all United States
94 community hospitals excluding rehabilitation and long-term acute care hospitals. The sampling
95 strategy selected hospitals within states that have state inpatient databases according to defined
96 strata based on ownership, bed size, teaching status, urban/rural location, and region¹⁰. All
97 discharges from sampled hospitals for the calendar year were then selected for inclusion into
98 NIS. To allow extrapolation for national estimates, both hospital and discharge weights are
99 provided. Detailed information on the design of the NIS is available at [http://www.hcup-](http://www.hcup-
100 us.ahrq.gov)

101 NIS captures discharge-level information on primary and secondary diagnoses and
102 procedures, discharge vital status, and demographics on several million discharges per year. Data
103 elements that could directly or indirectly identify individuals are excluded. The unit of analysis is
104 the discharge rather than the individual; discharges are therefore all considered independent. A
105 unique anonymous hospital identifier allows for linkage of discharge data to an NIS data set with

106 hospital characteristics. To protect subject confidentiality, NIS data only provides hospital-
107 specific identifiable information (e.g., hospital rurality, but not the rurality of patient residence).

108 We included all patients with a primary or secondary discharge diagnosis of stroke
109 (International Classification of Diseases, Ninth Revision diagnosis codes [ICD-9-CM] 433.01,
110 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.91, 436) at the time of hospital admission,
111 from January 2002 through September 2015. IVT administration was determined using ICD-9
112 procedure code 99.10.

113 We excluded patients with a diagnosis of acute myocardial infarction, pulmonary
114 embolism, malignancy (solid tumor without metastasis, lymphoma, metastatic cancer),
115 transferred to index hospital from another hospital, elective admissions, cases with missing
116 race/ethnicity and/or sex, and enrollment in a clinical trial (ICD-9-CM code V70.7). Please refer
117 to Supplemental Tables 1-3 for the full list of ICD-9 codes.

118

119 **Sociodemographic, Clinical, and Hospital Factors**

120 Individuals were categorized into the following age groups: <18 years, 18-44 years, 45-
121 64 years, 65-84 years, and ≥ 85 years. They were also categorized by sex (women/men),
122 race/ethnicity (White, Black, Hispanic, Asian/Pacific Islander (API), Native American, other,
123 missing), primary payer (Medicare, Medicaid, private, self-pay, no charge, other pay, missing),
124 and hospital location/teaching status (urban teaching, urban non-teaching, rural). Race/ethnicity
125 was determined from two HCUP administrative data elements of race and ethnicity. If the source
126 supplied race and ethnicity in separate data elements, then ethnicity took precedence over race.
127 Records with missing race/ethnicity were placed into an independent category of “Missing Race”
128 and were included in the analysis. Risk of mortality was determined by the Risk of Mortality

129 Subclass Category¹¹. Presence of the following comorbid conditions were assessed:
130 hypertension, dyslipidemia, alcohol abuse, obesity, smoking history, coronary artery disease,
131 atrial fibrillation, and Charlson Comorbidity Index¹² (which consists of 17 comorbidities;
132 Supplemental Table 3).

133

134 **Statistical Analyses**

135 National trends were estimated following HCUP methodological standards (which
136 adopted a design change in 2012), with appropriate trend weights. The observed yearly national
137 IVT utilization from 2002 to quarter 3 of 2015 was estimated using proc surveyfreq in SAS. For
138 the following demographic, comorbidities, and hospital factors, we conducted national
139 estimations by year, as well as by IVT utilization status: sex, age, race/ethnicity, national quartile
140 of household income by zip code, third-party payer, hospital region/teaching status, coronary
141 artery disease, atrial fibrillation or flutter, hypertension, dyslipidemia, obesity, smoking, alcohol
142 use, Charlson Comorbidity Index, and Risk of Mortality Subclass. Any factors with an observed
143 association with both year and with IVT utilization in univariate analysis or trend analysis
144 meaningfully in either clinical or epidemiological ways were considered as confounders that
145 could impact the temporal trend effects of IVT. To systematically compare temporal trends, we
146 divided the study period 2002-2015 into two periods - 2002-2008 (*Period 1*) and 2009-2015
147 (*Period 2*).

148 The temporal trend effect in IVT was tested using survey-weighted logistic models,
149 adjusting for sex, age, race/ethnicity, national quartile of household income by zip code,
150 insurance, hospital region, hospital location/teaching status, hypertension, diabetes, dyslipidemia,
151 obesity, coronary artery disease, peripheral artery disease, atrial fibrillation, congestive heart

152 failure, Charlson Comorbidity Index, smoking history, and alcohol history. In addition to the
153 linear temporal trend, we compared first and second seven-year periods (*Period 1* vs. *Period 2*)
154 adjusting for the same covariates. For temporal trends in subgroups, we used the survey-logistic
155 procedure with subgroup categories in the DOMAIN statement
156 (https://www.hcupus.ahrq.gov/reports/methods/2003_02.jsp#sas) to request statistics for the
157 subpopulation. All data analyses were conducted using SAS (version 9.4; SAS Institute Inc,
158 Cary, NC).

159 The study was considered exempt from institutional review board given the use of
160 deidentified information. We followed the Strengthening the Reporting of Observational Studies
161 in Epidemiology (STROBE) reporting guideline¹³.

162

163 **Results:**

164 Among patients admitted with a diagnosis of AIS (weighted n=6,694,081), approximately
165 half were 65-84 years (50.5%), just under a quarter were 45-64 years (24.0%), and 21.5% were
166 ≥ 85 years of age (**Table 1**). More than half of the study population were women (53.9%). The
167 race/ethnic distribution was as follows: White (58.9%), Black (14.5%), Hispanic (6.6%), API
168 (2.2%), and other (2.1%). Nearly two thirds of patients had comorbid hypertension (61.4%) and
169 approximately one in four had diabetes (26.6%), coronary artery disease (23.9%), or atrial
170 fibrillation (22.4%). Medicare was the most common insurance type (70.3%), followed by
171 private (16.8%) and Medicaid (6.7%). The distribution by geography was as follows: South
172 (41.0%), Midwest (22.0%), Northeast (18.5%) and West (18.5%).

173 The overall use of IVT for AIS increased from 1.0% in 2002 to 6.8% in 2015, with an
174 overall adjusted annual relative ratio (AARR) of 1.15 (95% CI 1.14-1.16). Individuals aged 18-

175 44 years had the highest rate of IVT during the entire period starting in 2003 (**Figure 1**). Adults
176 18 years of age or greater had an increase in IVT over time, with those ≥ 85 years having the
177 most pronounced increase (AARR of 1.18, CI 1.17-1.19; Period 2 vs. Period 1 adjusted odds
178 ratio (aOR) of 3.66, CI 3.3-4.07) (**Table 2**). However, compared to those aged 18-44 years, those
179 who were ≥ 85 years were still markedly less likely to receive IVT in both Period 1 (aOR 0.23,
180 95% CI 0.21-0.26) and Period 2 (aOR 0.36, 95% CI 0.34-0.38; **Figure 2A**). Minors (age < 18)
181 had the second lowest rate of IVT in Period 1 and the lowest in Period 2, and they were the only
182 age group without a significant increase in IVT use over time (AARR 0.95, CI 0.88-1.03; Period
183 2 vs. Period 1 aOR of 0.94, CI 0.49, 1.77)(**Table 2**).

184 Women were less likely than men to receive IVT in Period 1 (aOR 0.81, 95% CI 0.78-
185 0.84; **Figure 2B**); this inequity narrowed such that women remained slightly less likely than men
186 to receive IVT in Period 2 (aOR 0.94, 95% CI 0.92-0.97; **Figure 2B**). Compared to Period 1,
187 women in Period 2 were about three times more likely than to receive IVT (aOR 2.98, 95% CI
188 2.75-3.23)(**Table 2**).

189 Across all races/ethnicities, IVT rates increase; therefore, individuals were more likely to
190 receive IVT in Period 2 vs. Period 1 (White population OR 2.63, 95% CI 2.42-2.86; Black
191 population aOR 3.03, 95% CI 2.65-3.48; Hispanic population aOR 3.13, 95% CI 2.66-3.69;
192 Asian/Pacific Islander population aOR 2.84, 95% CI 2.28-3.52; other race/ethnicity aOR 3.18,
193 95% CI 2.65-3.81) (**Table 2**). In Period 1, Hispanic individuals were less likely than their non-
194 Hispanic White counterparts to receive IVT (aOR 0.81, 95% CI 0.69-0.94; **Figure 2C**), but the
195 inequity resolved in Period 2 (aOR 0.96, 95% CI 0.91-1.02; **Figure 2C**). Inequities in IVT for
196 Black compared to White individuals with stroke improved without resolving. In Period 1,
197 compared to White individuals, Black individuals were less likely to receive IVT (Period 1 aOR

198 0.71, 95% CI 0.63-0.79; Period 2 aOR 0.81, 95% CI 0.78-0.85; **Figure 2C**). Compared to Period
199 1, Black individuals in Period 2 were three times more likely to receive IVT (aOR 3.03; 95% CI
200 2.65-3.48; **Table 2**).

201 In Period 1, compared to those who were privately insured, individuals with Medicare
202 were less likely to receive IVT, even accounting for age (aOR 0.59, 95% CI 0.56-0.62; **Figure**
203 **2D**). This disparity improved but persisted in Period 2 (aOR 0.75, 95% CI 0.72-0.77; **Figure**
204 **2D**). Compared to Period 1, those with Medicare were three times more likely to receive IVT in
205 Period 2 (aOR 2.99, 95% CI 2.76-3.24; **Table 2**). Those with Medicaid insurance had a similar
206 trend of marginal improvement in equity from Period 1 (aOR 0.61, 95% CI 0.55-0.67; **Figure**
207 **2D**) to Period 2 (aOR 0.77, 95% CI 0.73-0.81; **Figure 2D**), with Period 2 vs. Period 1 aOR of
208 2.97 (95% CI 2.65-3.33; **Table 2**).

209 Compared to those treated at rural hospitals, those treated at urban non-teaching and
210 urban teaching hospitals were more likely to receive IVT in Period 1 (urban non-teaching vs.
211 rural: aOR 1.80, 95% CI 1.52-2.12; urban teaching vs rural: aOR 3.17, 95% CI 2.65-
212 3.80)(**Figure 2E**). Over time, IVT use increased in both rural and urban hospitals, but at a higher
213 rate in urban hospitals, thus increasing the disparities in Period 2 (urban non-teaching vs. rural:
214 aOR 2.58, 95% CI 2.33-2.85; urban teaching vs. rural: aOR 3.90, 95% CI 3.55-4.28; **Figure 2E**),
215 with Period 2 vs. Period 1 aORs of 2.90 (95% CI 2.66-3.16) and 2.48 (95% CI 2.23-2.76) for
216 urban non-teaching and urban teaching hospitals, respectively (**Table 2**).

217

218 **Discussion:**

219 This is the first study to assess temporal trends in IVT in the United States by numerous
220 key sociodemographic and geographic characteristics, including race/ethnicity, sex, age,

221 insurance, hospital teaching status, and geographic location. This study confirms steadily
222 increasing IVT use across all ages in adults, with the fastest growth in those over 85 years. The
223 sex inequity in IVT improved to near complete resolution in the second half of the study period.
224 Inequities in IVT for Hispanic individuals resolved. Marked inequities in IVT remain for Black
225 individuals despite improvements over time. Individuals with Medicare and Medicaid insurance
226 remained less likely to receive IVT compared to privately-insured individuals, despite modest
227 improvements over time. The inequities by geographic location continued to worsen, such that
228 those admitted to rural hospitals were nearly three times less likely to receive IVT compared to
229 those admitted to urban non-teaching hospitals and nearly 4 times less likely to receive IVT
230 compared to those admitted to urban teaching hospitals, a finding consistent with recently
231 published data⁹.

232 Individuals with AIS ≥ 85 years had the steepest relative growth in IVT. This corroborates
233 a previous study examining trends from 2005 to 2010³, where individuals ≥ 85 years showed the
234 most rapid increase in IVT, mostly in urban and high-volume hospitals. Similarly, a study using
235 Get With the Guidelines-Stroke data¹⁴ and a recent study in Austria¹⁵ from their national Stroke
236 Unit Registry noted a similarly dramatic increase in patients > 85 years of age and > 80 years.
237 Despite the increase in IVT, its absolute rates of use remained low in this age group. It is unclear
238 whether this is due to patients presenting outside the therapeutic window, inability to determine
239 last known well time in those who live alone, concerns about adverse events, or contraindications
240 due to comorbidities. The under-utilization of IVT in individuals under the age of 18 is likely
241 due to limited evidence of efficacy in this age group, lack of FDA-approval, atypical
242 presentations, and lower index of suspicion for stroke.

243 This is the first study to show resolution of disparities in IVT for Hispanic individuals.
244 However, race inequities remain. This study corroborates a previous NIS study that showed that
245 Black individuals were less likely to receive IVT than White individuals^{7,8}. A previous study
246 using the NIS database in 2004-2010 noted under-administration in Black patients regardless of
247 presentation to primary stroke centers.⁸ Potential reasons for the marked disparity for Black
248 individuals could include provider implicit bias or discrimination,¹⁶ or longer time to
249 presentation from factors such as poor access to care,^{17,18} medical mistrust¹⁹ and differences in
250 stroke preparedness (i.e. the ability to recognize signs and symptoms of stroke, knowledge to call
251 911, and action to call 911).^{20,21} It could also be due to systematic differences in quality of care at
252 hospitals where Black patients most often present.⁷

253 This study is the first to show an improvement in sex disparities in IVT. It is widely
254 recognized that women are less likely to receive IVT compared to men. Factors contributing to
255 sex differences in thrombolytic rates for women include delays in presentation²², atypical
256 presentations²³, underlying system-level factors⁷, inability to determine last known well time,
257 and provider bias²⁴. More research is needed to determine what has led to the reductions in sex
258 differences, but more widespread use of stroke pathways may be a factor.

259 This study is the first to evaluate nationwide temporal trends in receipt of IVT by
260 insurance type. The profound differences in IVT use by insurance type highlight the need to
261 expand healthcare access and improve quality of care for those with government insurance. An
262 example of an initiative that was successful in augmenting use of IVT was Target: Stroke quality
263 initiative²⁵, which led to a quicker administration of IVT with better long-term outcomes in
264 Medicare beneficiaries.

265 This study confirms a persistent trend of worsening rural-urban disparities in IVT for AIS
266 in the early 21st century^{4,6,9}. This widening disparity occurred with the steady temporal growth in
267 IVT use in urban teaching hospitals; use of IVT in rural hospitals fluctuated in the young AIS
268 patients aged 19-44 from 2001 to 2009⁶. A study from 2012 to 2017 demonstrated a persistent,
269 steady gap in IVT use for rural populations⁹. The widening urban/rural gap could be explained
270 by poor hospital and emergency medical services staffing, access to specialists, long distance to
271 stroke centers, and stroke literacy. These issues could be mitigated by expansion of telestroke
272 networks²⁶ and community outreach.

273 These sociodemographic and geographic inequities are likely due to individual, system,
274 and societal factors^{3,4,6-9,27}; therefore a multipronged approach is needed to address them.
275 Barriers to elimination of inequities include: (1) fundamental drivers of inequities, namely
276 unequal distribution of wealth, education, and employment opportunities; (2) historical and
277 ongoing structural and systemic racism which have disproportionately burdened Black
278 communities with poverty, food insecurity, housing instability, and other adverse social
279 determinants of health, and led to the likelihood of Black individuals having poor access to
280 care^{18,28} or receiving care in under-resourced, under-performing hospitals; (3) ineffective
281 messaging around stroke symptoms in lower income, Black, and Hispanic populations^{20,21}; (4)
282 provider-level factors, such as unconscious bias²⁹, racism³⁰, and hesitancy to treat the elderly
283 with IVT;³ (5) patient-level factors, such as women being more likely to live alone²² and delays
284 in presentation¹⁷, and (6) clinical factors such as atypical clinical presentations²³.

285 The study is limited by its cross-sectional design and lack of patient-level zip codes and
286 stroke specific data such as hospital stroke center designation, last known well times, stroke
287 severity, and individualized considerations for IVT use (e.g., personal/goals of care decisions and

288 medical contraindications not addressed by the exclusion criteria). Additionally, administrative
289 data (e.g., race/ethnicity, diagnosis) are prone to misclassification and coding errors. We
290 excluded individuals who were transferred in, so we may have underestimated IVT rates.
291 However, hospitals usually provide IVT prior to transfer, so we suspect these numbers are low.
292 The strengths of this study include that it is nationally representative, with key hospital-level
293 factors, sociodemographic characteristics, and comorbidities.

294 Further studies are needed to develop an understanding of reasons underlying persistent
295 inequities as well as recent improvements (e.g., resolution in inequities faced by Hispanic
296 individuals). It will be critical to elucidate the extent to which these inequities are caused by
297 system-, provider-, society-, and patient-level factors. Developing a more nuanced understanding
298 of the causes for persistent inequities in IVT will inform the development of effective
299 interventions for reducing them.

300

301 **Conclusions:**

302 From 2002 through 2015, IVT for AIS in the United States increased steadily in various
303 strata, with some encouraging trends of rapidly growing use of IVT among individuals ≥ 85 years
304 and a resolution of disparities for Hispanic individuals. Despite these encouraging trends, only 1
305 in 15 AIS patients received IVT, and inequities remain for Black patients, women, those with
306 Medicaid or Medicare insurance, and individuals admitted to rural hospitals. Further studies can
307 help us better understand these trends and design interventions aimed at eliminating inequities in
308 IVT for AIS.

309

310 **Disclosures**

311 Dr. Joynt Maddox receives research support from the National Heart, Lung, and Blood
312 Institute (R01HL143421 and R01HL164561), National Institute of Nursing Research
313 (U01NR020555) National Institute on Aging (R01AG060935, R01AG063759, and
314 R21AG065526), and National Center for Advancing Translational Sciences (UL1TR002345)
315 and from Humana. She also serves on the Health Policy Advisory Council for the Centene
316 Corporation (St. Louis, MO) and as an Associate Editor for the Journal of the American Medical
317 Association (JAMA).

318 Dr Towfighi receives research support from the National Institute of Neurological Disorders and
319 Stroke (R01NS093870) and National Institute of Minority Health and Health Disparities
320 (P50MD017366).

321

322 **References:**

- 323 1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR,
324 Medeghri Z, Machnig T, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute
325 ischemic stroke. *N Engl J Med.* 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656
- 326 2. National Institute of Neurological D, Stroke rt PASSG. Tissue plasminogen activator for
327 acute ischemic stroke. *N Engl J Med.* 1995;333:1581-1587. doi:
328 10.1056/NEJM199512143332401
- 329 3. George BP, Asemota AO, Dorsey ER, Haider AH, Smart BJ, Urrutia VC, Schneider EB.
330 United States trends in thrombolysis for older adults with acute ischemic stroke. *Clin*
331 *Neurol Neurosurg.* 2015;139:16-23. doi: 10.1016/j.clineuro.2015.08.031
- 332 4. Gonzales S, Mullen MT, Skolarus L, Thibault DP, Udoeyo U, Willis AW. Progressive
333 rural-urban disparity in acute stroke care. *Neurology.* 2017;88:441-448. doi:
334 10.1212/WNL.0000000000003562
- 335 5. Joo H, Wang G, George MG. Use of intravenous tissue plasminogen activator and
336 hospital costs for patients with acute ischaemic stroke aged 18-64 years in the USA.
337 *Stroke Vasc Neurol.* 2016;1:8-15. doi: 10.1136/svn-2015-000002
- 338 6. Kansara A, Chaturvedi S, Bhattacharya P. Thrombolysis and outcome of young stroke
339 patients over the last decade: insights from the Nationwide Inpatient Sample. *J Stroke*
340 *Cerebrovasc Dis.* 2013;22:799-804. doi: 10.1016/j.jstrokecerebrovasdis.2012.05.002
- 341 7. Faigle R, Urrutia VC, Cooper LA, Gottesman RF. Individual and System Contributions
342 to Race and Sex Disparities in Thrombolysis Use for Stroke Patients in the United States.
343 *Stroke.* 2017;48:990-997. doi: 10.1161/STROKEAHA.116.015056

- 344 8. Aparicio HJ, Carr BG, Kasner SE, Kallan MJ, Albright KC, Kleindorfer DO, Mullen MT.
345 Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist
346 at Primary Stroke Centers. *J Am Heart Assoc.* 2015;4:e001877. doi:
347 10.1161/JAHA.115.001877
- 348 9. Hammond G, Luke AA, Elson L, Towfighi A, Joynt Maddox KE. Urban-Rural Inequities
349 in Acute Stroke Care and In-Hospital Mortality. *Stroke.* 2020;51:2131-2138. doi:
350 10.1161/STROKEAHA.120.029318
- 351 10. HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP).
352 Agency for Healthcare Research and Quality. www.hcup-us.ahrq.gov/nisoverview.jsp.
353 2006-2017. Accessed 03/01.
- 354 11. McCormick PJ, Lin HM, Deiner SG, Levin MA. Validation of the All Patient Refined
355 Diagnosis Related Group (APR-DRG) Risk of Mortality and Severity of Illness
356 Modifiers as a Measure of Perioperative Risk. *J Med Syst.* 2018;42:81. doi:
357 10.1007/s10916-018-0936-3
- 358 12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with
359 ICD-9-CM administrative databases. *J Clin Epidemiol.* 1992;45:613-619. doi:
360 10.1016/0895-4356(92)90133-8
- 361 13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative
362 S. The Strengthening the Reporting of Observational Studies in Epidemiology
363 (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med.*
364 2007;147:573-577. doi: 10.7326/0003-4819-147-8-200710160-00010
- 365 14. Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, Bhatt DL, Grau-
366 Sepulveda MV, Peterson ED, Fonarow GC. Temporal trends in patient characteristics and

- 367 treatment with intravenous thrombolysis among acute ischemic stroke patients at Get
368 With The Guidelines-Stroke hospitals. *Circ Cardiovasc Qual Outcomes*. 2013;6:543-549.
369 doi: 10.1161/CIRCOUTCOMES.111.000303
- 370 15. Marko M, Posekany A, Szabo S, Scharer S, Kiechl S, Knoflach M, Serles W, Ferrari J,
371 Lang W, Sommer P, et al. Trends of r-tPA (Recombinant Tissue-Type Plasminogen
372 Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke.
373 *Stroke*. 2020;51:1240-1247. doi: 10.1161/STROKEAHA.119.027921
- 374 16. Green AR, Carney DR, Pallin DJ, Ngo LH, Raymond KL, Iezzoni LI, Banaji MR.
375 Implicit bias among physicians and its prediction of thrombolysis decisions for black and
376 white patients. *J Gen Intern Med*. 2007;22:1231-1238. doi: 10.1007/s11606-007-0258-5
- 377 17. Bradley EH, Herrin J, Wang Y, McNamara RL, Webster TR, Magid DJ, Blaney M,
378 Peterson ED, Canto JG, Pollack CV, Jr., et al. Racial and ethnic differences in time to
379 acute reperfusion therapy for patients hospitalized with myocardial infarction. *JAMA*.
380 2004;292:1563-1572. doi: 10.1001/jama.292.13.1563
- 381 18. Skinner J, Chandra A, Staiger D, Lee J, McClellan M. Mortality after acute myocardial
382 infarction in hospitals that disproportionately treat black patients. *Circulation*.
383 2005;112:2634-2641. doi: 10.1161/CIRCULATIONAHA.105.543231
- 384 19. Armstrong K, Ravenell KL, McMurphy S, Putt M. Racial/ethnic differences in physician
385 distrust in the United States. *Am J Public Health*. 2007;97:1283-1289. doi:
386 10.2105/AJPH.2005.080762
- 387 20. Lisabeth LD, Kleindorfer D. Stroke literacy in high-risk populations: a call for action.
388 *Neurology*. 2009;73:1940-1941. doi: 10.1212/WNL.0b013e3181c51aa3

- 389 21. Towfighi A, Skolarus LE. Inequities in Stroke Preparedness in Young Adults: What do
390 we Know and Where Should we Go? *Stroke*. 2020;51:3479-3481. doi:
391 10.1161/STROKEAHA.120.032612
- 392 22. Appelros P, Asberg S. Sex differences in stroke. *Handb Clin Neurol*. 2020;175:299-312.
393 doi: 10.1016/B978-0-444-64123-6.00021-7
- 394 23. Labiche LA, Chan W, Saldin KR, Morgenstern LB. Sex and acute stroke presentation.
395 *Ann Emerg Med*. 2002;40:453-460. doi: 10.1067/mem.2002.128682
- 396 24. Giralt D, Domingues-Montanari S, Mendioroz M, Ortega L, Maisterra O, Perea-Gainza
397 M, Delgado P, Rosell A, Montaner J. The gender gap in stroke: a meta-analysis. *Acta*
398 *Neurol Scand*. 2012;125:83-90. doi: 10.1111/j.1600-0404.2011.01514.x
- 399 25. Man S, Xian Y, Holmes DN, Matsouaka RA, Saver JL, Smith EE, Bhatt DL, Schwamm
400 LH, Fonarow GC. Target: Stroke Was Associated With Faster Intravenous Thrombolysis
401 and Improved One-Year Outcomes for Acute Ischemic Stroke in Medicare Beneficiaries.
402 *Circ Cardiovasc Qual Outcomes*. 2020;13:e007150. doi:
403 10.1161/CIRCOUTCOMES.120.007150
- 404 26. Adcock AK, Choi J, Alvi M, Murray A, Seachrist E, Smith M, Findley S. Expanding
405 Acute Stroke Care in Rural America: A Model for Statewide Success. *Telemed J E*
406 *Health*. 2020;26:865-871. doi: 10.1089/tmj.2019.0087
- 407 27. Ramirez L, Kim-Tenser MA, Sanossian N, Cen S, Wen G, He S, Mack WJ, Towfighi A.
408 Trends in Acute Ischemic Stroke Hospitalizations in the United States. *J Am Heart Assoc*.
409 2016;5. doi: 10.1161/JAHA.116.003233
- 410 28. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who
411 treat blacks and whites. *N Engl J Med*. 2004;351:575-584. doi: 10.1056/NEJMsa040609

- 412 29. Hall WJ, Chapman MV, Lee KM, Merino YM, Thomas TW, Payne BK, Eng E, Day SH,
413 Coyne-Beasley T. Implicit Racial/Ethnic Bias Among Health Care Professionals and Its
414 Influence on Health Care Outcomes: A Systematic Review. *Am J Public Health*.
415 2015;105:e60-76. doi: 10.2105/AJPH.2015.302903
- 416 30. Churchwell K, Elkind MSV, Benjamin RM, Carson AP, Chang EK, Lawrence W, Mills
417 A, Odom TM, Rodriguez CJ, Rodriguez F, et al. Call to Action: Structural Racism as a
418 Fundamental Driver of Health Disparities: A Presidential Advisory From the American
419 Heart Association. *Circulation*. 2020;142:e454-e468. doi:
420 10.1161/CIR.0000000000000936
- 421
- 422

423 **Figure Legends**

424 **Figure 1.** Proportion of acute ischemic stroke patients who received IVT by age from 2002 to
425 2015 (unadjusted)

426 **Figure 2 A.** Dichotomized comparison of IVT use between *Period 1* vs. *Period 2* by age

427 **Figure 2B.** Dichotomized comparison of IVT use between *Period 1* vs. *Period 2* by sex

428 **Figure 2C.** Dichotomized comparison of IVT use between *Period 1* vs. *Period 2* by

429 race/ethnicity

430 **Figure 2D.** Dichotomized comparison of IVT use between *Period 1* vs. *Period 2* by insurance

431 **Figure 2E.** Dichotomized comparison of IVT use between *Period 1* vs. *Period 2* by hospital

432 location/teaching status

433

Table 1. Patient and hospital characteristics of overall cohort (weighted N=6,694,081)

Age, years	Weighted N	% (mean ± SE)
<18	17,097	0.3±0.01
18-44	254,399	3.8±0.03
45-64	1,606,396	24.0±0.09
65-84	3,379,649	50.5±0.07
≥85	1,436,540	21.5±0.07
Sex		
Women	3,606,177	53.9±0.06
Men	3,086,823	46.1±0.06
Missing	1,081	0.02±0
Race/ethnicity		
White	3,942,986	58.9 ±0.4
Black	971,841	14.5±0.2
Hispanic	441,458	6.6±0.2
Asian/Pacific islander	149,256	2.2±0.06
Native American	22,736	0.3±0.02
Other	138,349	2.1±0.08
Missing	1,027,454	15.4±0.4
Comorbidities		
Hypertension	4,107,033	61.4±0.08
Diabetes	1,783,535	26.6±0.07
Dyslipidemia	2,740,402	40.9±0.2
Coronary artery disease	1,601,515	23.9±0.08
Atrial fibrillation	1,501,288	22.4±0.07
Congestive heart failure	1,043,455	15.6±0.06
Peripheral artery disease	60,065	0.9±0.01
Obesity	451,209	6.7±0.04
Smoking	575,040	8.6±0.07

Alcohol abuse	150,854	2.3±0.02
Charlson Comorbidity Index		
0	5,160,840	77.1±0.06
1	1,013,298	15.1±0.05
2	361,693	5.4±0.03
3+	158,250	2.4±0.02
Risk of Mortality Subclass		
Minor	1,619,730	24.2±0.09
Moderate	2,845,438	42.5±0.1
Major	1,365,900	20.4±0.06
Extreme	814,571	12.2±0.06
Missing	47,737	0.7±0.1
Insurance		
Medicare	4,702,599	70.3±0.1
Medicaid	451,058	6.7±0.07
Private (including HMO)	1,122,618	16.8±0.1
Self-Pay	257,539	3.9±0.05
No Charge	25,637	0.4±0.02
Other Pay	124,216	1.9±0.04
Missing	10,414	0.2±0.01
Household income		
<\$45,000	1,835,301	27.4±0.3
\$45-60,000	1,681,387	25.1±0.2
\$60-80,000	1,570,078	23.5±0.2
>\$80,000	1,464,540	21.9±0.3
Missing	142,775	2.1±0.05
Hospital Location/Teaching Status		
Rural	870,369	13.0±0.2
Urban Non-Teaching	2,844,987	42.5±0.3
Urban Teaching	2,953,365	44.1±0.4

Geographic Region			434
Northeast	1,237,316	18.5±0.3	435
Midwest	1,472,593	22.0±0.3	436
South	2,745,210	41.0±0.4	437
West	1,238,961	18.5±0.3	437

438

439 SE: Standard error

440 HMO: Health Maintenance Organization

Table 2: Rate of IVT from 2002 to 2015 by age groups, race/ethnicity, sex, insurance, and hospital location/teaching status

	Rate of IVT use, percent (95% CI)		aOR*(95% CI)	AARR†(95% CI)
	Period 1 (2002-2008)	Period 2 (2009-2015)	Period 2 vs Period 1 (2009-2015 vs 2002-2008)	2002-2015
Age				
<18 years	1.42 (0.72, 2.11)	1.33 (0.81, 1.84)	0.94 (0.49, 1.77)	0.95 (0.88, 1.03)
18-44 years	3.87 (3.51, 4.23)	8.77 (8.36, 9.19)	2.39 (2.14, 2.67)	1.13 (1.11, 1.14)
45-64 years	2.51 (2.34, 2.69)	6.2 (6.01, 6.39)	2.56 (2.37, 2.77)	1.14 (1.13, 1.15)
65-84 years	1.64 (1.53, 1.75)	4.37 (4.23, 4.5)	2.74 (2.53, 2.95)	1.14 (1.13, 1.15)
≥85 years	0.93 (0.84, 1.01)	3.31 (3.17, 3.44)	3.66 (3.3, 4.07)	1.18 (1.17, 1.19)
Sex				
Women	1.55 (1.44, 1.66)	4.47 (4.33, 4.6)	2.98 (2.75, 3.23)	1.16 (1.15, 1.17)
Men	1.9 (1.78, 2.02)	4.72 (4.57, 4.86)	2.56 (2.38, 2.76)	1.14 (1.13, 1.15)
Race/ethnicity				
White	1.86 (1.71, 2)	4.75 (4.62, 4.88)	2.63 (2.42, 2.86)	1.14 (1.13, 1.15)
Black	1.32 (1.15, 1.49)	3.9 (3.73, 4.07)	3.03 (2.65, 3.48)	1.16 (1.14, 1.18)
Hispanic	1.51 (1.27, 1.74)	4.56 (4.31, 4.81)	3.13 (2.66, 3.69)	1.17 (1.15, 1.19)

Asian/Pacific Islander	1.79 (1.4, 2.17)	4.91 (4.54, 5.27)	2.84 (2.28, 3.52)	1.15 (1.13, 1.18)
Other	1.69 (1.41, 1.96)	5.17 (4.82, 5.52)	3.18 (2.65, 3.81)	1.15 (1.13, 1.18)
Insurance				
Medicare	1.5 (1.39, 1.6)	4.35 (4.21, 4.48)	2.99 (2.76, 3.24)	1.15 (1.14, 1.16)
Medicaid	1.54 (1.38, 1.7)	4.46 (4.23, 4.68)	2.97 (2.65, 3.33)	1.15 (1.13, 1.16)
Private (including HMO)	2.51 (2.34, 2.68)	5.72 (5.51, 5.92)	2.36 (2.18, 2.55)	1.13 (1.12, 1.14)
Other pay	1.96 (1.75, 2.16)	4.69 (4.45, 4.93)	2.47 (2.19, 2.77)	1.14 (1.12, 1.16)
Hospital location/teaching status				
Rural	0.78 (0.66, 0.9)	1.57 (1.43, 1.7)	2.02 (1.72, 2.38)	1.11 (1.09, 1.13)
Urban non-teaching	1.40 (1.29, 1.5)	3.94 (3.74, 4.14)	2.90 (2.66, 3.16)	1.17 (1.16, 1.18)
Urban teaching	2.44 (2.19, 2.68)	5.84 (5.66, 6.02)	2.48 (2.23, 2.76)	1.13 (1.12, 1.15)

* adjusted odds ratio of receiving IVT comparing 2009-2015 vs 2002-2008. Adjusted for female sex, age, race/ethnicity, national quartile of household income by zip code, insurance, hospital region, hospital location/teaching status, hypertension, diabetes, dyslipidemia, obesity, coronary artery disease, peripheral artery disease, atrial fibrillation

† slope of log linear of IVT administration from 2002-2015

IVT: Intravenous thrombolysis

aOR: adjusted odds ratio


AARR: adjusted annual relative ratio

CI: Confidence interval


HMO: Health Maintenance Organization

441

442 **Figure 1.**
443
444



445 **Figure 2A**




459 *adjusted for female sex, age, race/ethnicity, national quartile of household income by zip code, insurance, hospital
460 region, hospital location/teaching status, hypertension, diabetes, dyslipidemia, obesity, coronary artery disease,
461 peripheral artery disease, atrial fibrillation, congestive heart failure, Charlson Comorbidity Index, smoking history,
462 and alcohol history.

463
464
465
466
467
468
469
470
471
472
473
474
475
476
477

478 **Figure 2B**


479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494



*adjusted for female sex, age, race/ethnicity, national quartile of household income by zip code, insurance, hospital region, hospital location/teaching status, hypertension, diabetes, dyslipidemia, obesity, coronary artery disease, peripheral artery disease, atrial fibrillation, congestive heart failure, Charlson Comorbidity Index, smoking history, and alcohol history.

495 **Figure 2C**


496
497
498
499
500
501
502
503
504
505
506
507
508
509
510



*adjusted for female sex, age, race/ethnicity, national quartile of household income by zip code, insurance, hospital region, hospital location/teaching status, hypertension, diabetes, dyslipidemia, obesity, coronary artery disease, peripheral artery disease, atrial fibrillation, congestive heart failure, Charlson Comorbidity Index, smoking history, and alcohol history.

511 **Figure 2D**


512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527



*adjusted for female sex, age, race/ethnicity, national quartile of household income by zip code, insurance, hospital region, hospital location/teaching status, hypertension, diabetes, dyslipidemia, obesity, coronary artery disease, peripheral artery disease, atrial fibrillation, congestive heart failure, Charlson Comorbidity Index, smoking history, and alcohol history.

528 **Figure 2E**

529
530
531
532
533
534
535
536
537
538
539
540
541
542
543



*adjusted for female sex, age, race/ethnicity, national quartile of household income by zip code, insurance, hospital region, hospital location/teaching status, hypertension, diabetes, dyslipidemia, obesity, coronary artery disease, peripheral artery disease, atrial fibrillation, congestive heart failure, Charlson Comorbidity Index, smoking history, and alcohol history.